SNG.L - Synairgen plc

LSE - LSE Delayed Price. Currency in GBp
14.10
0.00 (0.00%)
At close: 4:30PM GMT
Stock chart is not supported by your current browser
Previous Close14.10
Open13.75
Bid0.00 x 0
Ask0.00 x 0
Day's Range13.75 - 13.75
52 Week Range6.98 - 32.00
Volume47,793
Avg. Volume245,725
Market Cap12.882M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.90
Earnings DateMay 15, 2018 - May 21, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est35.00
  • How Synairgen plc’s (LON:SNG) Recent Earnings Fared Against The Long Term Trend
    Simply Wall St.2 months ago

    How Synairgen plc’s (LON:SNG) Recent Earnings Fared Against The Long Term Trend

    Understanding how Synairgen plc (AIM:SNG) is performing as a company requires looking at more than just a years’ earnings. Today I will run you through a basic sense check toRead More...

  • Synairgen plc (AIM:SNG): How Does It Impact Your Portfolio?
    Simply Wall St.5 months ago

    Synairgen plc (AIM:SNG): How Does It Impact Your Portfolio?

    If you are a shareholder in Synairgen plc’s (AIM:SNG), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...

  • Reuters10 months ago

    AstraZeneca aims to escape drug sales trough in second half

    AstraZeneca, struggling with loss of patents on blockbusters like cholesterol pill Crestor, reported another quarter of falling drug sales on Thursday as it awaits pivotal clinical trial data that may revive its fortunes. Chief Executive Pascal Soriot believes 2017 will mark the trough for the British group, as it starts to put generic losses behind it and builds up sales of recently launched and experimental cancer medicines. Industry analysts, on average, had forecast revenue of $5.4 billion and earnings of 82 cents, according to Thomson Reuters data.

  • PR Newswire11 months ago

    Synairgen plc: Additional Positive Data in Lung Fibrosis

    SOUTHAMPTON, England, March 10, 2017 /PRNewswire/ -- - Phase I c linical trial s cheduled to start in H2 2017   Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces ...